RussianPatents.com

Composition for treating and preventing osteoarthritis, osteoporosis and osteoarthrosis

IPC classes for russian patent Composition for treating and preventing osteoarthritis, osteoporosis and osteoarthrosis (RU 2521227):

A61P19/02 - for joint disorders, e.g. arthritis, arthrosis
A61P19/00 - Drugs for skeletal disorders
A61K36/899 - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J0003000000; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L)
A61K35/64 - Insects, e.g. royal jelly
A61K31/352 -
Another patents in same IPC classes:
Method of treating degenerative and inflammatory-degenerative arthropathies / 2519119
Method involves the para-articular injections of the dispersed biomaterial Alloplant dissolved in a physiological solution into an involved joint. That is combined with the endoarticular injections of the biomaterial into the involved joint. The protracted treatment involves 1-5 procedures of the pairwise para- and endoarticular injections of the biomaterial 8-12 ml every 8-12 days. The dispersed biomaterial Alloplant for injections is dissolved at the ratio of 50 mg of the biomaterial to 15-20 ml of the physiological solution.
Novel bicyclic heterocyclic compound Novel bicyclic heterocyclic compound / 2518073
Claimed invention relates to novel compound of formula (1) or its pharmaceutically acceptable salt, possessing SNS inhibiting properties. In general formula R1 represents (1) hydrogen atom, (2) halogen atom, (3) C1-6alkyl group or (4) C1-6halogenalkyl group (where R1 can be present in any substitutable position of benzene or pyridine ring); L represents (1) simple bond, (2) -O- or (3) -CH2O- (where L can be present in position 5 or 6 of condensed cycle); R2 represents (1) C6-10aryl group (C6-10aryl group is optionally condensed with C3-6cycloalkane), optionally substituted with substituent(s), X represents carbon atom or nitrogen atom. Other values of radicals are given in the invention formula.
Method for preparing injection synovial substitute Method for preparing injection synovial substitute / 2517237
Lyophilisate of a complex of sulphated and non-sulphated glycosaminoglycans and proteins is prepared first; further, a lyophilisate of collagen is prepared; the final stage involves preparing 2% complex of sulphated and non-sulphated glycosaminoglycans and proteins in distilled water and mixing it with the lyophilisate of collagen to a viscosity of 8.0-8.2 in relation to distilled water; the preparation is bottled and sterilised with fast electron flux in a dose of 18+5 kGy.
Method for prevention of posttraumatic gonarthrosis / 2516951
Knee joint injury is simulated in rats by 5 intra-articular administrations of the antioxidant ethoxydol 5 mg/kg every second day.
Some chemical structures, compositions and methods Some chemical structures, compositions and methods / 2513636
Invention refers to new compounds of structural formula I that possess inhibitory activity on phosphatidyl inositol-3-kinase (PI3-kinase). In formula I: B represents group of formula II:, wherein Wc represents 6-10-merous aryl, q is equal to 0, 1, 2, 3 or 4; X is absent or represents -(CH(R9))z-, z is equal to 1; Y represents -N(R9)-; Wd represents R1 and R2 represents C1-6alkyl or halogeno; R3 represents hydrogen or C1-6alkyl; and in each case R9 independently represents hydrogen or C1-6alkyl.
Phenyl alkyl piperazines, which modulate tnf activity Phenyl alkyl piperazines, which modulate tnf activity / 2512567
Invention relates to phenyl alkyl piperazines of formula (I) , in which: R1 represents independently on each other hydrogen atom, halogen atom, (C1-C5)alkyl group, (C1-C5)halogenalkyl group, (C1-C2)perfluoroalkyl group, (C1-C5)alkoxyl group or (C1-C2)perfluoroalkoxyl group; R2 stands for (C1-C5)alkyl group or (C1-C5)alkoxyl group, R3 represents (C1-C5)alkyl group; A represents =CH- and =N-; in form of base or additive salt with acid. Invention also relates to pharmaceutical composition for modulation of activity of TNF-alpha, which contains claimed compounds, and to method of their obtaining.
Preventive and therapeutic agent for inflammatory disease Preventive and therapeutic agent for inflammatory disease / 2511406
Present invention refers to biotechnology and medicine. What is presented is a method for preventing or treating an inflammatory disease, comprising the stages of producing an NR10 antibody having NR10-neutralising activity, and selecting an antibody inhibiting IL-31-dependent cell line growth, and administering the antibody to a patient with an inflammatory disease that is atopic dermatitis, chronic dermatitis, rheumatism or osteoarthritis.
Novel chemical compounds - 2,4-diamino-1,3,5-triazine derivatives for preventing and treating human and animal diseases Novel chemical compounds - 2,4-diamino-1,3,5-triazine derivatives for preventing and treating human and animal diseases / 2509770
Invention relates to a 2,4-diamino-1,3,5-triazine derivative of general formula I, having protein kinase inhibitor properties, use thereof and a pharmaceutical composition based thereon. In general formula I Y is CH2, CHR', O, S, S(O) or S(O)2; X1, X2, X3 are independently selected from a CH groups or N; R1 is a C1-8 aliphatic group, C3-8 cycloalkyl, C6-10 aryl, ethylene-dioxyphenyl, methylene dioxyphenyl, pyridyl, each of which is optimally substituted with one or more identical or different groups R"; R' is hydrogen, OH, halogen, such as F, Cl, Br, I, or carboxyl or carboxamide, optimally N-substituted with (C1-6)alkyl, or cyano or halo(C1-8)alkyl, (C1-8)alkoxy, piperidinyl, optimally substituted with methyl; R" is R' or RD; R21, R22, R23, R24 are independently selected from groups F, Cl, Br, I, CN, (C1-16)alkyl; furthermore, R21 and R22 and/or R23 and R24 can be combined and represent one oxo (=O) group or together with a carbon atom can form a spirocycle containing 3 to 7 carbon atoms; furthermore, R21 and R24 together with two carbon atoms can form an aliphatic or aromatic ring containing 4 to 8 atoms, optionally substituted with one or more groups R'; RD is an oxo group =O or =S.
Composition for treating and preventing osteoarthritis and osteoarthrosis / 2509569
Invention refers to pharmaceutical industry, namely to a composition for treating and preventing osteoarthritis and osteoarthrosis. The composition for treating and preventing osteoarthritis and osteoarthrosis contains a powder or an extract of a dry plant specified in a group: burdock, dandelion, cowberry, birch, St.-John's wort, golden-rod, nettle, peppermint, licorice, cinquefoil, tormentil, brier, Greek valerian, valerian, corn, holy thistle, oat, agrimony, everlasting flower, ginseng, sage, starwort, squash, willow, wild strawberry, chicory, wheat-grass, artichoke, bilberry, marigold, horse radish, garlic, aspen, knotgrass, plantain, inula, Fagopyrum rubricaulis, chamomile, balm lemon, blue poppy, cudweed, tripartite bur-marigold; a male larval bee lyophilisate and a quercetine or dihydroquercetine, or rutin powder in certain proportions.
Phenoxypyridinylamide derivatives, and their use in treatment of pde4-mediated disease states Phenoxypyridinylamide derivatives, and their use in treatment of pde4-mediated disease states / 2509077
Invention refers to a compound of formula (I):
Agent for treating and preventing locomotor diseases / 2516963
Agent is prepared by boiling milled raw hard wheat grain in water, filtering, adding goat milk to the prepared brew, boiling, adding olive and sea buckthorn oil to prepare an oil mixture; further boiling milled herbal raw material in water, including chamomile blossom, elevated part of wormwood, elevated part of St. John's wort, rose hips, elevated part of mint, filtering, mixing the brew with the oil mixture to a homogenous state.
Method for biocompatible polymeric structure formation Method for biocompatible polymeric structure formation / 2512950
Invention refers to medicine, namely to traumatology and biotechnology, and may be used for the biocompatible polymeric structure formation in bone tissues. That is provided by a puncture approach to a filled cavity in the bone tissues. That is followed by filling the cavity with a polymeric gel compound containing 55-97.7 wt % of the biocompatible polymer polylactide of a particle size of 50 to 100 mcm, 0.3-45 wt % of magnetic nanoparticles of ferric oxide of a particle size of 10 to 100 nm, the gelling agent maltodexrin in the amount of 0.5 to 50 wt % of the weight of mixed polymer and magnetic nanoparticles, as well as distilled water in the amount of 0.5 to 100 wt % of the weight of a dry mixture of the polymer, magnetic nanoparticles and gelling agent. A solid three-dimension structure is formed. That is accompanied with heating the compound throughout by exposing to an alternating magnetic field at frequency 500 kHz and amplitude 500 E for 3-5 minutes. Where appropriate slow down the process of heating the compound, it is additionally exposed to a direct magnetic field at amplitude 1000 E applied either to the whole formed volume, or locally depending on the problem to be solved.
Pharmaceutical compositions of ipidacrine and using them for treating and preventing solution of continuity Pharmaceutical compositions of ipidacrine and using them for treating and preventing solution of continuity / 2512743
Invention refers to medicine and pharmacology. The invention describes using ipidacrine for treating the locomotor diseases related to the solution of continuity. The above locomotor diseases are fractures, including delayed bone consolidation, delayed knitting, delayed fracture union, pathologic fracture, non-union fracture, and pseudoarthrosis. A pharmaceutical composition for treating the locomotor diseases contains ipidacrine as an active ingredient in an effective amount of 3 to 300 mg per a dose, and a pharmaceutically acceptable excipients. The composition is presented in the form of a tablet or a capsule.
Derivative, containing condensed ring structure, and its application in medicine Derivative, containing condensed ring structure, and its application in medicine / 2512547
Claimed invention relates to compounds, represented by formula (I) , where X1 and X2 independently represent CH or N; ring U represents benzene ring, pyrazole ring, 1,2,4-oxadiazole ring, 1,2,4-thiadiazole ring, isothiazole ring, oxazole ring, pyridine ring, thiazole ring or thiophene ring, m represents integer number, which has values from 0 to 1; n represents integer number, which has values from 0 to 3; R1 represents hydroxygroup or C1-6 alkyl; R2 represents any of (1)-(3): (1) halogen atom; (2) hydroxygroup; (3) C1-6 alkyl or C1-6 alkoxy, each of which can independently contain any group, selected from group of substituents α; group of substituents α includes fluorine atom and hydroxygroup, or its pharmaceutically acceptable salt. Invention also relates to pharmaceutical composition, possessing inhibiting activity with respect to xanthenes oxidase, including formula (I) compound or its pharmaceutically acceptable salt as active ingredient.
Composition for treating and preventing osteoarthritis and osteoarthrosis / 2509569
Invention refers to pharmaceutical industry, namely to a composition for treating and preventing osteoarthritis and osteoarthrosis. The composition for treating and preventing osteoarthritis and osteoarthrosis contains a powder or an extract of a dry plant specified in a group: burdock, dandelion, cowberry, birch, St.-John's wort, golden-rod, nettle, peppermint, licorice, cinquefoil, tormentil, brier, Greek valerian, valerian, corn, holy thistle, oat, agrimony, everlasting flower, ginseng, sage, starwort, squash, willow, wild strawberry, chicory, wheat-grass, artichoke, bilberry, marigold, horse radish, garlic, aspen, knotgrass, plantain, inula, Fagopyrum rubricaulis, chamomile, balm lemon, blue poppy, cudweed, tripartite bur-marigold; a male larval bee lyophilisate and a quercetine or dihydroquercetine, or rutin powder in certain proportions.
Method of preventing purulent-inflammatory complications in treatment of trauma-orthopedic patients with application of apparatuses of external fixation / 2508062
Invention relates to medicine, namely to traumatology and orthopedics, and can be used for prevention of purulent-inflammatory complications from application of apparatuses of external fixation in the process of treatment of patients in traumatology and orthopedics. For this purpose transosseous osteosynthesis of long tubular bones is performed by introduction of wires and intraosseous rods of compression-distraction apparatus of external fixation into their proximal and distal fragments. Antimicrobial substance is applied on the surface of wires and intraosseous rods before their introduction into proximal and distal fragments, as well as on degreased surface of patient's skin in places of entrance and exit of wires and intraosseous rods. As antimicrobial means used is gel-like nanostructured composite implant. It is replaced on degreased surface of skin in places of entrance and exit of wires and intraosseous rods 2-4 weeks after initial application. Composite implant includes platelet-enriched autoplasma, mixed in ratio 1:1.0-2.0 with granules of complex alloplastic preparation on the basis of hydroxyapatite, which contains 50-60 wt % of collagen. Said complex alloplastic preparation additionally contains 0.08-2.8 wt % of colloid solution of zerovalent metal silver Ag0, or gold Au0, or copper Cu0, or palladium Pd0, or platinum Pt0, which is introduced into its granules at preparation stage. Size of introduced colloid zerovalent metal nanoparticles constitutes from 2 nm to 40 nm.
Method for improving transdermal permeability of therapeutic or cosmetic topical preparations, method for dermal administration of liquid xenon Method for improving transdermal permeability of therapeutic or cosmetic topical preparations, method for dermal administration of liquid xenon / 2506944
Invention refers to cosmetic and pharmaceutical industry and represents a method for improving the transdermal permeability of therapeutic or cosmetic topical preparations involving the dermal administration of 1.0 to 300.0 vol. % of liquid xenon as a part of an acceptable neutral carrier or a therapeutic or cosmetic preparation.
Method of treating skeletal complications in patients with lytic long bone metastases / 2505299
Intramedullary osteosynthesis is followed by a bone grafting of a lytic lesion with using a composition prepared as follows: Veroklast dry concentrate 4 mg is dissolved in water for injections 1 ml; the prepared solution is mixed with Kollapan granules 2 g and incubated at room temperature until absorbed completely.
Sulphonamide compounds and use thereof Sulphonamide compounds and use thereof / 2502730
Invention relates to sulphonamide compounds of formula or pharmaceutically acceptable salts thereof, wherein A is phenyl, optionally substituted with 1 or 2 halogen atoms, C1-6 alkyl group, trifluoromethyl group, C1-6 alkoxy group or -SCH3 group, thiophenyl, optionally substituted with a C1-C6 alkyl group or a halogen atom, pyridinyl, optionally substituted with a halogen atom, naphthalenyl or dihydroindenyl; R1 denotes the following formulae or [in formulae (R1a) and (R1b) Ar1 denotes the following formulae , or (each R5 and R6 independently denotes a hydrogen atom, a halogen atom, a C1-6 alkyl group optionally substituted with up to three halogen atoms, C1-6 lower alkoxy group optionally substituted with up to three halogen atoms); Ar2 denotes the following formulae , or (each R7 and R8 independently denotes a hydrogen atom, a hydroxyl group, a halogen atom, a C1-6 alkyl group optionally substituted with up to three halogen atoms or a C1-6 lower alkoxy group optionally substituted with up to three halogen atoms, an amine group, a nitro group, a C2-6 acyl group, or R7 and R8 together form -CH2CH2O-; R9 is a hydrogen atom or - J-COOR10; J is a covalent bond, alkylene containing 1 to 5 carbon atoms, alkenylene containing 2 to 5 carbon atoms or alkynylene containing 2 to 5 carbon atoms, where one carbon atom in said alkylene groups can be substituted with an oxygen atom, a sulphur atom, NR11, CONR11 or NR11CO in any chemically acceptable position; R11 is a hydrogen atom; and R10 is a hydrogen atom); and p equals 0 or 1]; R2 is a C1-6 alkyl group; each R3 and R4 is independently a C1-6 alkyl group; * denotes an asymmetric carbon atom; and m equals an integer from 1 to 3. The invention also relates to a medicinal agent for stimulating PTH secretion.
Pharmaceutical composition with anti-inflammatory, cardio- and chondroprotective activity, action preventing gastropathies caused by nsaid, and method for preparing it Pharmaceutical composition with anti-inflammatory, cardio- and chondroprotective activity, action preventing gastropathies caused by nsaid, and method for preparing it / 2502507
Invention refers to a pharmaceutical composition with anti-inflammatory, cardio- and chondroprotective activity, action preventing gastropathies caused by non-steroidal anti-inflammatory drugs. The above composition contains sodium diclofenac 5 - 25%, quercetin in the form of dihydrate or an anhydrous substance 10 - 40%, polyvinylpyrrolidone 10 - 50%, sodium lauryl sulphate 0.25 - 10%, microcrystalline cellulose 20 - 40%, croscarmellose sodium salt 1 - 15% and magnesium stearate 0.25 -5.0% at total weight of the composition. The invention also concerns the method for preparing the specified compound.
Water-soluble bactericidal reparative composition / 2521209
Composition includes a bactericidal substance - catapol - in amount of 2.1-2.5 wt %, zosterin in amount of 1.1-5.0 wt % and distilled water.

FIELD: medicine.

SUBSTANCE: composition for treating and preventing osteoarthritis and osteoarthrosis contains a powder or an extract of a dry plant specified in a group: burdock, dandelion, cowberry, birch, St.-John's wort, golden-rod, nettle, peppermint, licorice, cinquefoil, tormentil, brier, Greek valerian, valerian, corn, holy thistle, oat, agrimony, everlasting flower, ginseng, sage, starwort, squash, willow, wild strawberry, chicory, wheat-grass, Jerusalem artichoke, bilberry, marigold, horse radish, garlic, aspen, knotgrass, plantain, inula, Fagopyrum rubricaulis, chamomile flowers, balm lemon, blue poppy, cudweed, tripartite bur-marigold; a male larval bee lyophilisate and a quercetine or dihydroquercetine, or rutin powder in certain proportions.

EFFECT: composition is effective for treating and preventing osteoarthritis and osteoarthrosis, maintains the nutrition of the osteoarticular apparatus, growth and regeneration of connective tissue with no side effects, as well as enabled collagen synthesis for the recovery of connective and cartilage tissue, with preserving the anti-inflammatory and analgesic effect.

2 ex

 

The invention relates to compositions for improving the functional state of the musculoskeletal system.

Centuries-old medical experience shows that virtually every man occasionally pain in the back and joints of the limbs (Nordemar R. back Pain. - M.: Medicine, 1988. - 144 C.). Common rheumatoid arthritis is the most severe form of inflammatory joint disease is 3%, and non-inflammatory (degenerative changes (osteoarthritis) about 10% of the population of the planet (Kessel VP When aching joints. - M.: Knowledge, 1979. - 96 S.).

Currently, for the treatment of articular diseases using various medications (urdan, aspirin, reopirin diclofenac, aspirin, antibiotics and others)who are ineffective. There are more than 100 non-specific pharmacological tools for the treatment of diseases of the joints, but it is too early to speak about drug inflation, as this problem is far from resolved due to lack of therapeutic effectiveness, neudovletvorennosti distant consequences.

Osteoarthritis (OA) is a progressive chronic disease that mainly affects the joints most exposed to mechanical stress, such as hip and knee. Under such conditions, the entire joint is affected in the ser and processes of destruction and reconstruction, which inevitably affect the anatomy and functioning of the joint, affecting all joint components, such as cartilage, subchondral bone and synovial tissue. OA, therefore, is the result of an interaction of systemic factors (eg, age, or obesity) and local factors (eg, trauma or high stress), which, in turn, modulated by many precipitating factors, possibly in combination with infection or inflammatory processes of various etiologies. In the past, the cartilage was considered responsible for the occurrence of OA and the only target organ. However, recently received a large amount of data that the subchondral bone can be a pathogenetic factor responsible for the emergence and development of OA.

Taking into account this complex events over the years attempts were made to treat the condition by eliminating individual causal processes and the use of local or systemic anti-inflammatory drugs or intra-articular injections of hyaluronic acid. It was later proposed the use of drugs that affect bone metabolism, such as diphosphonates. Limited use also found some of the drugs described in more or less arbitrarily, such as protective agents (anthraquinones, chondroiti the sulfate and so on), but their real therapeutic ability is very low and inconsistent.

It is established that morphological changes in the structure of subchondral bone is preceded by the defeat of the articular cartilage. Disorders of microcirculation in the subchondral articular departments are characterized by obstruction of venous outflow with increased intraosseous pressure, which causes excruciating pain.

It is known tool that has immunomodulation, antiviral, antibacterial, antioxidant, membrane, stimulates the regeneration of cartilage and connective tissue properties containing substances from the group of chondroprotective - chondroitin sulphate and glucosamine, as well as antibacterial and formative components with auxiliary substances (.RU No. 2349339, publ. 2009.03.20).

It is known for the treatment of diseases of the joints, contains chondroitin sulfate, a sulfoxide, a preservative, emulgel base (.RU No. 2353349, publ. 27.04.2009).

It is known for the treatment of diseases of the joints, containing a salt of glucosamine, salt of chondroitin sulfate and dimethyl sulfoxide (.RU No. 2239438, publ. 2006.03.20 and Patea No. 6528 - similar. Publ. 2006.02.24).

Known medical profilakticheski means "Glucosamine Sulfate", used for the treatment and prevention of musculoskeletal (Biologically active d is the additives to food. - M.: Nauka, 2002, p.47). The drug, "Glucosamine sulfate" includes glucosamine. Glucosamine has chondroprotective activity. If it enters the human body it is delivered to the cartilage and other tissues, where it is synthesized in chondroitin sulfate. Chondroitin sulfate is a major source of building blocks for connective tissue. He is involved in the formation of cartilage, ligaments, tendons, is present in the walls of blood vessels, bronchi, skin and mucous membranes. Chondroitin sulfate is an effective tool for cartilage repair and formation of synovial fluid to reduce muscle fatigue, also for the consolidation of any of the connective tissue of the human body. However, "Glucosamine sulfate" is a monotherapy. You know the "Sostavit"that contains comprehensive medical profilakticheskuyu composition, which, along with derivatives included glucosamine chondroitin sulfate, herbs, vitamins, calcium and enzymes (Biologically active additives to food. - M.: Nauka, 2002, 49). Known composition provides nutritional support of bone and articular apparatus, promotes the growth and regeneration of connective tissue and stimulates collagen and substances necessary for the growth of cartilage.

Known use in the compositions of the drone RASPA is and to prevent osteoporosis as an active ingredient. The composition can be made in powder, tablet and capsule form (path No. 2412616 from 27.02.2011 g).

From the documents US 200201165169 from 2002, KR 20030002377 from 2003 it is known the use of quercetin and rutin for the treatment and prevention of osteoporosis.

From the document US 20041211024 A1, publ. 24.06.2004 known composition for the treatment and prevention of osteoarthritis, rheumatoid arthritis and similar diseases, containing extract of nettle and quercetin. This song is the closest analogue of the claimed invention.

A disadvantage of the known tools is that they do not allow to raise the tone of the venous system, to improve venous return, thereby to relieve the feeling of heaviness and swelling in the legs associated with joint disease.

The present invention is to provide a composition of active substances, effectively acting on the elimination of pain in the joint.

This object is achieved in that the proposed composition for the treatment and prevention of osteoarthritis and osteoarthritis of the joints, characterized in that it contains an extract or powder of dried plants, selected from the group of: burdock, dandelion, cowberry, birch, St. John's wort, goldenrod, nettle, mint, licorice, and p. white, erect cinquefoil, rose, Polemonium caeruleum L., Valerian, cook the UzA, milk Thistle, oat, agrimony, immortelle, ginseng, sage, starwort, pumpkin, willow, wild strawberry, chicory, wheat grass, artichokes, blueberries, calendula, horseradish, garlic, aspen, knotweed (Polygonum aviculare), plantain, elecampane, Krasnoznamennaya buckwheat, chamomile flowers, lemon balm, cornflower blue, cottonweed, a series of tripartite; lyophilized drone brood and powder, quercetin, or dihydroquercetin, or routine in the following ratio of components in parts (1-5):(1-4):1 respectively.

The composition may be in the form of tablets weighing 500 mg Composition tablets 500 mg:

Dihydroquercetin - 100 mg,

Lyophilized drone brood - 100 mg,

Powder, dandelion roots - 200 mg,

Auxiliary shape-forming components 100 mg

The composition may be in the form of capsules weight of 400 mg of the capsule 400 mg:

Dihydroquercetin - 100 mg,

Lyophilized drone brood - 100 mg,

Powder, dandelion roots - 200 mg

The composition may be in the form of powder active ingredients in the specified proportions in a single dosage 400 mg

The present invention is that the pharmacological effects of, on the one hand, should cause the proliferation of chondrocytes, on the other, change the state of the matrix of cartilage and restore collagen frame around bones and cartilage, improve krovosnabgenie is, to promote the regeneration of bone, bone marrow, cartilage, synovial fluid, which is possible only in the case of the integrated effects of components included in the claimed composition.

Recently managed to establish that the disease of metabolism are the primary, and changes in bones and joints with subsequent disease - secondary, respectively, targeted regulation of metabolism not only stops the deformation of the joints, regardless of the stage of the disease, but also helps to restore the morphological structure of cartilage.

The fate of bone tissue, its formation and destruction depend on the volume of the flowing blood from changing hyperemic, stagnant and anemic States, thus, improve blood circulation by increasing capillary permeability increases regeneration in the bones, bone marrow, cartilage, synovial fluid.

Any of the plants mentioned in the application, allows the body to produce chondrocytes (cartilage cells). These plants are producing factors in the regeneration of cartilage tissue (Glycosides - taraxacin, taraxacin - these protective agents; Vitamin PP). Pharmacological effects of glycosides, are intended to cause, on the one hand, the proliferation of chondrocytes, and on the other, changing the state of mA is the matrix of cartilage. Vitamin PP is vital for the synthesis of sex hormones (estrogen, progesterone, testosterone), as well as hormones produced by the adrenal cortex (cortisol), thyroid gland (thyroxin) and pancreas (insulin). Cortisone, thyroxin and insulin actively influence the recovery of the cartilage and the formation of chondrocytes. The release of growth hormone causes the formation in the liver insulin-like growth factor (CRF-1), which is the strongest anabolic regeneration in the bones, bone marrow, cartilage, synovial fluid.

Drone brood is an aid donor androgenic steroids: prolactin, estradiol, progesterone, testosterone, amino acids: glycine, alanine, and others, has a stimulating effect on the formation of chondrocytes (cartilage cells), restoration of synovial fluid. Drone brood gives power to the chondrocytes that they have not perished and survived. As a result, the multiplication of chondrocytes goes faster.

The chondrocytes are produced in cartilage, but in the body there is a reserve of bone cells that can transform into cartilage tissue. Used constituent ingredients of the application, acting through the blood provide to the reproduction, restoration, education chondrocytes in the cartilage and from the reserve of bone cells. Application is dihydroquercetin restores, regulates and increases your metabolism (metabolism), i.e. is the catalyst of metabolic processes, which in turn leads to increased all the above ingredients in multiplication of chondrocytes, the recovery matrix and sinoville fluid. In addition, dihydroquercetin and drone brood increase the mineralization of bone tissue, which decreases with arthritis and arthritis resulting from osteoporosis. Application of dihydroquercetin increases blood flow, increases capillary permeability, which, in turn, increases the power of the chondrocytes in the cartilage tissue. At the same time when use of the drug is recovered, the cavities, resulting in osteoporosis, which also leads to improved blood flow in the cartilage tissue.

It is the chondrocytes synthesize components of the cartilage matrix - elastin, collagen, glycoproteins, proteoglycans, etc. Hence, the yield and nutrition of chondrocytes in cartilage tissue entail reduce pain, and restore cartilage.

In the preferred embodiment the effective daily dose is at least about 1 mg, more preferred from 1 mg to 500 mg of active molecules.

The composition of the tablets 500 mg:

Dihydroquercetin - 100 mg,

Lyophilized drone brood - 100 mg,

Powder, dandelion roots - 200 mg,

Subsidiary of FMR is obrazuyuschie components 100 mg

The composition may be in the form of capsules weight of 400 mg.

The capsule 400 mg:

Dihydroquercetin - 100 mg,

Lyophilized drone brood - 100 mg,

Powder, dandelion roots - 200 mg

The composition may be in the form of powder weight of 400 mg.

The powder 400 mg:

Dihydroquercetin - 100 mg,

Lyophilized drone brood - 100 mg,

Powder, dandelion roots - 200 mg

Examples of product receipt.

Example 1

Take:

powder of dihydroquercetin in the amount of 10 kg,

- lyophilized drone brood in the amount of 10 kg,

- crushed powder, dandelion roots in the amount of 10 kg

The mixture is stirred until homogeneous, then the finished product

capsulebuy.

Example 2

Take:

powder of dihydroquercetin in the amount of 100 kg,

- lyophilized drone brood in the amount of 400 kg,

- crushed powder, dandelion roots in the amount of 500 kg

The mixture is stirred until homogeneous, after which tabletirujut.

For the experiments was chosen composition containing 1 tablet: dihydroquercetin - 100 mg, lyophilized drone brood -100 mg, powder, dandelion roots - 200 mg. Reception cycles 1 tablet 2 times a day for 30 days, then a break of 14 days. The duration of treatment 9 months.

The proposed treatment composition was applied medicinska center "Secrets of longevity" , Penza in 30 patients with osteoarthritis of the lower extremities, complicated by synovitis, periarthritis, chondro - and osteomalasia, varicose disease, osteoporosis. Age from 54 to 72 years. Disease duration from 1 to 10 years.

Patients noted pain in his legs, stiffness, limitation of motion in the joints, reduced quality of life. Objective examination notice swelling of the knee joints, naturalnoi region of the hip joints, deformation and defigure knee joints, increase of skin temperature in the area of knee and hip joints, limitation of movement in them.

As a result of the treatment all patients had improvement: reduction or disappearance of pain in the knee and hip joints, increased range of motion in them, according to thermometry decreased the temperature of the skin surface. According to rheovasography and flow rate of muscle blood flow improves blood supply to the area affected limb, was not observed or slow down the formation of subchondral cysts, improved the quality of life of patients, pushed back the time of arthroplasty.

Treatment of patients with osteoarthritis with opportunistic infections, reduces inflammation, improves trophic tissues and metabolism of cartilage and periarticular tissues, normalizes krovoobrashenie, a positive effect on the remodeling of the subchondral bone in the affected limb. Improvement occurred after the first round of the composition. Increased increased motor activity and decrease in pain, which led to remission, improve patients ' quality of life and postpone the time of arthroplasty.

Therefore, when treating patients claimed composition improves the quality of life of patients, prevents the development of disease and disability of patients in the early stages of osteoarthritis of the I-II and relegated the time of arthroplasty patients with stage III-IV disease.

Introduction to a person or domestic animal composition or compositions in the form of feed shows the improvement of bone regeneration in the treatment of fractures. Composition method stimulates bone formation, increase bone mineral density in the growth stage and optimize peak bone mass. In particular, the composition may provide optimal bone growth in childhood. Specified food composition helps to prevent depression of the bone, in particular the rarefaction of the bones caused by age, in mammals, or rarefaction of the bones associated with prolonged hospitalization. It reduces the risk of osteoporosis and improves recovery after fracture. In addition, it contributes to the formation of the tion of cartilage in mammals, prevents osteoarthritis in humans and domestic animals, which leads to increased activity or mobility of the individual.

The composition provides support power osteoarticular apparatus, as well as the growth and renewal of connective tissue without adverse effect, and also allows the synthesis of collagen to restore connective tissue, cartilage tissue with preservation of the anti-inflammatory and analgesic effect.

1. Composition for the treatment and prevention of osteoarthritis and osteoarthritis of the joints, characterized in that it contains an extract or powder of dried plants, selected from the group of: burdock, dandelion, cowberry, birch, St. John's wort, goldenrod, nettle, mint, licorice, and p. white, erect cinquefoil, rose, Polemonium caeruleum L., Valerian, corn, milk Thistle, oat, agrimony, immortelle, ginseng, sage, starwort, pumpkin, willow, wild strawberry, chicory, wheat grass, artichokes, blueberries, calendula, horseradish, garlic, aspen, knotweed (Polygonum aviculare), plantain, elecampane, Krasnoznamennaya buckwheat, chamomile flowers, lemon balm, cornflower blue, cottonweed, a series of tripartite; lyophilized drone brood and powder, quercetin, or dihydroquercetin, or routine in the following ratio of components in parts (1-5):(1-4):1 respectively.

2. The composition according to claim 1, which which can be done in the form of tablets, capsules, powder.

 

© 2013-2014 Russian business network RussianPatents.com - Special Russian commercial information project for world wide. Foreign filing in English.